Nothing in that presentation we all didn't already know. I could easily present the next one if required. I'm left wondering how 'prestigious' QIDP really is if it was awarded for a compound that then requires another year of testing/data just to define to the FDA exactly what type of compound it is? How is it 'fast-tracked' when it still needs to go through years of human trials like every other drug? These are genuine questions that have occurred to me after following this company for some time.
Ann: Recce Presented at FNN/Shaw and Partners Investor Conference, page-2
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $115.9M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 52.0¢ | 49.0¢ | $164.9K | 323.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28482 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 27141 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RCE (ASX) Chart |